Marrow cell transplantation for infantile hypophosphatasia
- PMID: 12674323
- DOI: 10.1359/jbmr.2003.18.4.624
Marrow cell transplantation for infantile hypophosphatasia
Abstract
An 8-month-old girl who seemed certain to die from the infantile form of hypophosphatasia, an inborn error of metabolism characterized by deficient activity of the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP), underwent the first trial of bone marrow cell transplantation for this heritable type of rickets. After cytoreduction, she was given T-cell-depleted, haplo-identical marrow from her healthy sister. Chimerism in peripheral blood and bone marrow became 100% donor. Three months later, she was clinically improved, with considerable healing of rickets and generalized skeletal remineralization. However, 6 months post-transplantation, worsening skeletal disease recurred, with partial return of host hematopoiesis. At the age of 21 months, without additional chemotherapy or immunosuppressive treatment, she received a boost of donor marrow cells expanded ex vivo to enrich for stromal cells. Significant, prolonged clinical and radiographic improvement followed soon after. Nevertheless, biochemical features of hypophosphatasia have remained unchanged to date. Skeletal biopsy specimens were not performed. Now, at 6 years of age, she is intelligent and ambulatory but remains small. Among several hypotheses for our patient's survival and progress, the most plausible seems to be the transient and long-term engraftment of sufficient numbers of donor marrow mesenchymal cells, forming functional osteoblasts and perhaps chondrocytes, to ameliorate her skeletal disease.
Similar articles
-
Infantile hypophosphatasia: transplantation therapy trial using bone fragments and cultured osteoblasts.J Clin Endocrinol Metab. 2007 Aug;92(8):2923-30. doi: 10.1210/jc.2006-2131. Epub 2007 May 22. J Clin Endocrinol Metab. 2007. PMID: 17519318
-
Denaturing gradient gel electrophoresis analysis of the tissue nonspecific alkaline phosphatase isoenzyme gene in hypophosphatasia.Mol Genet Metab. 2002 Feb;75(2):143-53. doi: 10.1006/mgme.2001.3283. Mol Genet Metab. 2002. PMID: 11855933
-
Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment.Nat Rev Endocrinol. 2016 Apr;12(4):233-46. doi: 10.1038/nrendo.2016.14. Epub 2016 Feb 19. Nat Rev Endocrinol. 2016. PMID: 26893260 Review.
-
Hypophosphatasia: phenotypic variability and possible Croatian origin of the c.1402g>A mutation of TNSALP gene.Coll Antropol. 2009 Dec;33(4):1255-8. Coll Antropol. 2009. PMID: 20102078
-
[Genetic basis for skeletal disease. Stem cell therapy for genetic bone disorders].Clin Calcium. 2010 Aug;20(8):1228-35. Clin Calcium. 2010. PMID: 20675934 Review. Japanese.
Cited by
-
Dual differentiation-exogenous mesenchymal stem cell therapy for traumatic spinal cord injury repair in a murine hemisection model.Stem Cells Int. 2013;2013:928982. doi: 10.1155/2013/928982. Epub 2013 Aug 20. Stem Cells Int. 2013. PMID: 24027587 Free PMC article. Review.
-
Asfotase alfa treatment for 1 year in a 16 year-old male with severe childhood hypophosphatasia.Osteoporos Int. 2018 Feb;29(2):511-515. doi: 10.1007/s00198-017-4267-x. Epub 2017 Oct 18. Osteoporos Int. 2018. PMID: 29046930
-
[Cell therapy in bone-healing disorders].Orthopade. 2010 Apr;39(4):449-62; quiz 463. doi: 10.1007/s00132-009-1583-7. Orthopade. 2010. PMID: 20182700 Review. German.
-
Rescue of severe infantile hypophosphatasia mice by AAV-mediated sustained expression of soluble alkaline phosphatase.Hum Gene Ther. 2011 Nov;22(11):1355-64. doi: 10.1089/hum.2010.210. Epub 2011 Jun 8. Hum Gene Ther. 2011. PMID: 21388343 Free PMC article.
-
Cell therapy in bone healing disorders.Orthop Rev (Pavia). 2010 Sep 23;2(2):e20. doi: 10.4081/or.2010.e20. Orthop Rev (Pavia). 2010. PMID: 21808710 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical